Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: Novartis’s US strategy for inclisiran; Roche under pressure over prices for Actemra in COVID; Lambda coronavirus variant poses new challenge for vaccines; GSK loses its oncology R&D head; and a look at expected Q3 approvals in the US.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 July 2021, including: Novartis AG’s US strategy for inclisiran; Roche Holding AG under pressure over prices for Actemra in COVID; Lambda coronavirus variant poses new challenge for vaccines; GlaxoSmithKline plc loses its oncology R&D head; and a look at expected Q3 approvals in the US.

These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider. 

Stories mentioned in this episode:

(Also see "Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran’s US Success" - Scrip, 6 Jul, 2021.)

(Also see "Shifting Goalposts For Vaccine Cos As Lambda Variant Rears Head" - Scrip, 7 Jul, 2021.)

(Also see "GSK's Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion" - Scrip, 7 Jul, 2021.)

(Also see "10 US Approval Decisions To Look Out For In Q3" - Scrip, 5 Jul, 2021.)

 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel